Pfizer Price to Free Cash Flow Ratio 2012-2026 | PFE

Historical price to free cash flow ratio values for Pfizer (PFE) since 2012.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Pfizer Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2026-09-15 27.55 14.32
2026-06-30 23.67 $1.92 12.30
2026-03-31 27.15 $1.66 16.37
2025-12-31 23.68 $1.59 14.91
2025-09-30 23.81 $1.82 13.09
2025-06-30 22.27 $2.18 10.20
2025-03-31 22.84 $1.97 11.61
2024-12-31 23.53 $1.73 13.63
2024-09-30 25.27 $1.44 17.54
2024-06-30 24.09 $0.84 28.63
2024-03-31 23.54 $0.89 26.31
2023-12-31 24.06 $0.84 28.66
2023-09-30 27.35 $1.42 19.27
2023-06-30 29.91 $1.85 16.16
2023-03-31 32.92 $3.53 9.33
2022-12-31 40.96 $4.54 9.02
2022-09-30 34.68 $4.10 8.46
2022-06-30 41.24 $4.97 8.30
2022-03-31 40.39 $5.55 7.27
2021-12-31 45.72 $5.23 8.74
2021-09-30 33.01 $5.21 6.33
2021-06-30 29.79 $3.73 7.99
2021-03-31 27.29 $2.39 11.43
2020-12-31 27.43 $2.16 12.69
2020-09-30 25.68 $1.87 13.73
2020-06-30 22.66 $2.29 9.88
2020-03-31 22.40 $2.12 10.56
2019-12-31 26.61 $1.86 14.33
2019-09-30 24.17 $1.99 12.18
2019-06-30 28.87 $2.07 13.97
2019-03-31 28.06 $2.27 12.37
2018-12-31 28.59 $2.32 12.34
2018-09-30 28.64 $2.68 10.70
2018-06-30 23.38 $2.63 8.89
2018-03-31 22.65 $2.51 9.01
2017-12-31 22.90 $2.45 9.35
2017-09-30 22.37 $2.27 9.87
2017-06-30 20.84 $2.23 9.34
2017-03-31 21.02 $2.29 9.17
2016-12-31 19.76 $2.33 8.47
2016-09-30 20.40 $2.15 9.50
2016-06-30 21.03 $2.21 9.53
2016-03-31 17.55 $2.30 7.64
2015-12-31 18.92 $2.12 8.91
2015-09-30 18.26 $2.25 8.11
2015-06-30 19.35 $2.16 8.97
2015-03-31 19.91 $2.13 9.33
2014-12-31 17.67 $2.47 7.15
2014-09-30 16.63 $2.37 7.01
2014-06-30 16.55 $2.61 6.34
2014-03-31 17.75 $2.51 7.07
2013-12-31 16.78 $2.39 7.02
2013-09-30 15.62 $2.27 6.88
2013-06-30 15.11 $2.00 7.54
2013-03-31 15.44 $2.01 7.68
2012-12-31 13.30 $2.05 6.48
2012-09-30 13.06 $2.04 6.40
2012-06-30 11.98 $1.94 6.18
2012-03-31 11.68 $2.15 5.44
2011-12-31 11.04 $2.36 4.68
2011-09-30 8.93 $2.49 3.59
2011-06-30 10.29 $2.75 3.74
2011-03-31 10.05 $2.60 3.86
2010-12-31 8.58 $1.23 6.96
2010-09-30 8.32 $1.08 7.67
2010-06-30 6.84 $0.86 7.97
2010-03-31 8.14 $0.93 8.73
2009-12-31 8.55 $2.18 3.92
2009-09-30 7.70 $2.45 3.15
2009-06-30 6.91 $2.40 2.88
2009-03-31 6.21 $2.47 2.52
2008-12-31 7.90 $2.45 3.22
2008-09-30 8.08 $2.07 3.91
2008-06-30 7.53 $2.16 3.48
2008-03-31 8.88 $1.94 4.59
2007-12-31 9.51 $1.65 5.75
2007-09-30 10.10 $1.74 5.81
2007-06-30 10.45 $1.61 6.51
2007-03-31 10.21 $1.78 5.72
2006-12-31 10.36 $2.14 4.85
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $157.995B $62.579B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $1071.528B 36.15
Johnson & Johnson (JNJ) United States $641.804B 24.52
AbbVie (ABBV) United States $462.493B 24.08
Merck (MRK) United States $357.370B 45.12
Roche Holding AG (RHHBY) Switzerland $349.105B 0.00
Novartis AG (NVS) Switzerland $265.214B 16.01
Novo Nordisk (NVO) Denmark $194.004B 10.81
Sanofi (SNY) France $105.050B 8.84
Bayer (BAYRY) Germany $56.081B 9.98
Innoviva (INVA) United States $1.510B 5.16